SCHEMBL2997780

SCHEMBL2997780

O=[N+]([O-])c1ccc(S(=O)(=O)C2CCN(c3nc(Cc4ccc(Cl)c(F)c4)cs3)CC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
HTR2A P28223 2/20 0.34
HTR2C P28335 2/20 0.34
KCNH2 Q12809 2/20 0.34
DRD2 P14416 1/20 0.34
DNM1L O00429 2/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
FPR2 P25090 2/20 0.32
PROKR1 Q8TCW9 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019649 0.93 MAPT (0.40) MAPTSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL3002715 0.92 MEN1 (0.39) MAPTSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL3020593 0.92 SMN1; SMN2 (0.39) MAPTSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL3019919 0.92 LMNA (0.36) MAPTSMN1; SMN2MEN1KMT2ADNM1L
SCHEMBL3012603 0.91 VCAM1 (0.37) MAPTPOLBALDH1A1KDM4ELMNA
SCHEMBL3007239 0.90 HTR2A (0.40) MAPTSMN1; SMN2NPC1RAB9AHTR2A
SCHEMBL3011420 0.90 HTR2A (0.42) MAPTSMN1; SMN2NPC1RAB9AHTR2A
SCHEMBL3010530 0.89 HTR2A (0.35) MAPTSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL3017935 0.89 HTR2A (0.35) MAPTSMN1; SMN2NPC1RAB9AHTR2A
SCHEMBL3016901 0.89 GBA1 (0.39) MAPTSMN1; SMN2KMT2ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.